Replimune Group (NASDAQ:REPL) Given New $27.00 Price Target at Piper Sandler

Replimune Group (NASDAQ:REPL – Get Free Report) had its price objective upped by equities researchers at Piper Sandler from $14.00 to $27.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler‘s price target points to a potential upside of 23.34% from the stock’s current price.

A number of other brokerages also recently commented on REPL. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective for the company in a research report on Friday, August 7th. JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, August 26th. Leerink Partners raised their target price on shares of Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. Wall Street Zen upgraded shares of Replimune Group from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. Finally, Wolfe Research upgraded Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Replimune Group presently has an average rating of “Moderate Buy” and an average price target of $18.17.

View Our Latest Analysis on Replimune Group

Replimune Group Price Performance

NASDAQ:REPL opened at $21.89 on Monday. Replimune Group has a twelve month low of $1.50 and a twelve month high of $23.54. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -7.85 and a beta of 0.93. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. The stock’s 50 day moving average price is $14.76 and its two-hundred day moving average price is $10.04.

Replimune Group (NASDAQ:REPL – Get Free Report) last released its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.24. Equities research analysts expect that Replimune Group will post -2.40 earnings per share for the current fiscal year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, Director Joseph P. Slattery sold 5,200 shares of the firm’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $21.80, for a total transaction of $113,360.00. Following the completion of the sale, the director owned 1,467 shares of the company’s stock, valued at $31,980.60. This trade represents a 78.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kapil Dhingra sold 21,500 shares of Replimune Group stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $19.00, for a total transaction of $408,500.00. Following the transaction, the director directly owned 21,669 shares of the company’s stock, valued at approximately $411,711. This trade represents a 49.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of REPL. Quantinno Capital Management LP lifted its position in Replimune Group by 782.7% during the first quarter. Quantinno Capital Management LP now owns 108,477 shares of the company’s stock worth $830,000 after acquiring an additional 96,188 shares during the last quarter. Montanova Capital LLC grew its position in shares of Replimune Group by 4.0% in the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock valued at $48,595,000 after purchasing an additional 168,000 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Replimune Group in the first quarter valued at approximately $921,000. Squarepoint Ops LLC bought a new position in shares of Replimune Group during the second quarter worth approximately $1,454,000. Finally, Deutsche Bank AG bought a new position in shares of Replimune Group during the second quarter worth approximately $857,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

(Get Free Report)

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.

Featured Stories

Analyst Recommendations for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.